Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors

RNA

Volumn 19, Issue 2, 2013, Pages 280-293

  Bak, Rasmus O ^a   Hollensen, Anne Kruse ^a   Primo, Maria Nascimento ^a   Sørensen, Camilla Darum ^a   Mikkelsen, Jacob Giehm ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Lentiviral vectors; MiRNA inhibition; Tough Decoy; TuD

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; NUCLEOTIDYLTRANSFERASE INHIBITOR; RNA POLYMERASE II;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

BINDING SITES; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; LENTIVIRUS; LUCIFERASES; MICRORNAS; NUCLEIC ACID CONFORMATION; RNA POLYMERASE II; RNA, MESSENGER;

EID: 84872556705     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.034850.112     Document Type: Article

References (47)

1. Ameres SL, Martinez J, Schroeder R. 2007. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130: 101-112.
2. An W, Telesnitsky A. 2001. Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. Virology 286: 475-482.
3. Bak RO, Stenderup K, Rosada C, Petersen LB, Moldt B, Dagnaes- Hansen F, Jakobsen M, Kamp S, Jensen TG, Dam TN, et al. 2011. Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol 11: 5.
4. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, et al. 2007. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13: 613-618.
5. Chang K, Elledge SJ, Hannon GJ. 2006. Lessons from Nature: MicroRNA-based shRNA libraries. Nat Methods 3: 707-714.
6. Choi WY, Giraldez AJ, Schier AF. 2007. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318: 271-274.
7. Davis S, Lollo B, Freier S, Esau C. 2006. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 34: 2294-2304.
8. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37: 1289-1295.
9. Ebert MS, Neilson JR, Sharp PA. 2007. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726.
10. Elbashir SM, LendeckelW, Tuschl T. 2001. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200.
11. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M, Naldini L. 2009. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6: 63-66.
12. Gilboa E, Mitra SW, Goff S, Baltimore D. 1979. A detailed model of reverse transcription and tests of crucial aspects. Cell 18: 93-100.
13. Guimaraes-Sternberg C, Meerson A, Shaked I, Soreq H. 2006. MicroRNA modulation of megakaryoblast fate involves cholinergic signaling. Leuk Res 30: 583-595.
14. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. 2008. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 47: 7482-7484.
15. Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
16. Haraguchi T, Ozaki Y, Iba H. 2009. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 37: e43.
17. Haraguchi T, Nakano H, Tagawa T, Ohki T, Ueno Y, Yoshida T, Iba H. 2012. A potent 2'-O-methylated RNA-based microRNA inhibitor with unique secondary structures. Nucleic Acids Res 40: e58.
18. Huntzinger E, Izaurralde E. 2011. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet 12: 99-110.
19. Hutvágner G, Simard MJ, Mello CC, Zamore PD. 2004. Sequence-specific inhibition of small RNA function. PLoS Biol 2: E98.
20. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J. 2005. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120: 623-634.
21. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. 2005. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 280: 16635-16641.
22. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. 2004. Nuclear export of microRNA precursors. Science 303: 95-98.
23. McDermott AM, Heneghan HM, Miller N, Kerin MJ. 2011. The therapeutic potential of microRNAs: Disease modulators and drug targets. Pharm Res 28: 3016-3029.
24. McIntyre GJ, Yu YH, Tran A, Jaramillo AB, Arndt AJ, Millington ML, Boyd MP, Elliott FA, Shen SW, Murray JM, et al. 2009. Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. Virol J 6: 184.
25. Medina PP, Slack FJ. 2009. Inhibiting microRNA function in vivo. Nat Methods 6: 37-38.
26. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR, Kay MA. 2000. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 1: 522-532.
27. Mullokandov G, Baccarini A, Ruzo A, Jayaprakash AD, Tung N, Israelow B, Evans MJ, Sachidanandam R, Brown BD. 2012. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat Methods 9: 840-846.
28. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable trans-duction of nondividing cells by a lentiviral vector. Science 272: 263-267.
29. Okada C, Yamashita E, Lee SJ, Shibata S, Katahira J, Nakagawa A, Yoneda Y, Tsukihara T. 2009. A high-resolution structure of the pre-microRNA nuclear export machinery. Science 326: 1275-1279.
30. Primo MN, Bak RO, Schibler B, Mikkelsen JG. 2012. Regulation of proinflammatory cytokines TNFα and IL24 by microRNA-203 in primary keratinocytes. Cytokine 60: 741-748.
31. Sakurai F, Furukawa N, Higuchi M, Okamoto S, Ono K, Yoshida T, Kondoh M, Yagi K, Sakamoto N, Katayama K, et al. 2012. Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a. Virus Res 165: 214-218.
32. Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I, Ganser A, Eder M. 2007. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res 35: e149.
33. Staunstrup NH, Madsen J, Primo MP, Li J, Liu Y, Kragh PM, Li R, Schmidt M, Purup S, Dagnaes-Hansen F, et al. 2012. Development of transgenic cloned pig models of skin inflammation by DNA transposon- directed ectopic expression of human β1 and α2 integrin. PLoS One 7: e36658.
34. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B. 2008. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 16: 557-564.
35. Tiscornia G, Tergaonkar V, Galimi F, Verma IM. 2004. CRE recombinase- inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci 101: 7347-7351.
36. Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. 2009. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther 17: 1527-1536.
37. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H. 2003. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4: 609-615.
38. Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 318: 1931-1934.
39. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci 101: 10380-10385.
40. Vermeulen A, Robertson B, Dalby AB, Marshall WS, Karpilow J, Leake D, Khvorova A, Baskerville S. 2007. Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA 13: 723-730.
41. Wang X, Han L, Zhang A, Wang G, Jia Z, Yang Y, Yue X, Pu P, Shen C, Kang C. 2011. Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells. Oncol Rep 25: 97-105.
42. Wiznerowicz M, Szulc J, Trono D. 2006. Tuning silence: Conditional systems for RNA interference. Nat Methods 3: 682-688.
43. Xie J, Ameres SL, Friedline R, Hung JH, Zhang Y, Xie Q, Zhong L, Su Q, He R, Li M, et al. 2012. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods 9: 403-409.
44. Young DD, Connelly CM, Grohmann C, Deiters A. 2010. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 132: 7976-7981.
45. Zeng Y, Wagner EJ, Cullen BR. 2002. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9: 1327-1333.
46. Zeng Y, Cai X, Cullen BR. 2005. Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 392: 371-380.
47. Zhang S, Chen L, Jung EJ, Calin GA. 2010. Targeting microRNAs with small molecules: From dream to reality. Clin Pharmacol Ther 87: 754-758.